MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Vanda Pharmaceuticals DSO Ratio 2011-2026 | VNDA
Annual DSO Ratio Vanda Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.9 | 74.6 | 64.1 | 47.3 | 42.5 | 41.5 | 42.4 | 54.4 | 38.9 | 50.7 | 54.2 | 26.6 | 23.3 | 16.1 | 18.9 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 85.9 | 16.1 | 45.4 |
Quarterly DSO Ratio Vanda Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.7 | 83.6 | - | 81 | - | - | - | 73.9 | 57.6 | 42.4 | - | 20.5 | 21.6 | 47.7 | - | 51.1 | 46.1 | 44.8 | 40.5 | 45.5 | 44.1 | 44.4 | 39.5 | 40.5 | 40.7 | 52.7 | 49.5 | 53.5 | 55.5 | 48.5 | 36.3 | 38.9 | 38.2 | 46.2 | 48.4 | 48.1 | 51.3 | 50.2 | 46.8 | 52.6 | 54 | 41.2 | 21.7 | 22.6 | 30.7 | 28.4 | 21.1 | 21.3 | 22.3 | 18.1 | 13.5 | 12.9 | 12.7 | 15.6 | 17.6 | 18.5 | 19.9 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 83.6 | 12.7 | 40.2 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
25.1 | $ 28.46 | 3.45 % | $ 319 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
Axsome Therapeutics
AXSM
|
105 | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Kamada Ltd.
KMDA
|
103 | $ 8.5 | -1.39 % | $ 260 M |  Israel |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Benitec Biopharma
BNTC
|
141 | $ 10.98 | -4.52 % | $ 452 M | USA |
 |
Compugen Ltd.
CGEN
|
60.8 | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
88.9 | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Curis
CRIS
|
103 | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Coherus BioSciences
CHRS
|
559 | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Cellectis S.A.
CLLS
|
94.5 | $ 3.34 | -4.02 % | $ 116 M |  France |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.24 | -2.97 % | $ 704 M | Canada |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.8 | -1.1 % | $ 120 M | USA |
 |
Iterum Therapeutics
ITRM
|
740 | $ 0.16 | -5.45 % | $ 3.15 M |  Irlanda |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |